Context Therapeutics (CNTX) Institutional Ownership $0.97 0.00 (-0.33%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)16TotalInstitutional Inflows(last 12 months)$24.33MNumber ofInstitutional Sellers(last 12 months)10TotalInstitutional Outflows(last 12 months)$3.81M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Qube Research & Technologies Ltd106,779$70K0.0%-38.7%0.119% 8/13/2025 Affinity Asset Advisors LLC518,025$339K0.0%-21.6%0.578% 8/13/2025 Walleye Capital LLC132,786$87K0.0%-21.4%0.148% 5/16/2025Ally Bridge Group NY LLC1,157,448$708K0.6%-26.6%1.290% 5/15/2025Landscape Capital Management L.L.C.41,216$25K0.0%-54.2%0.046% 5/14/2025Affinity Asset Advisors LLC660,589$404K0.0%-34.9%0.736% 2/17/2025Velan Capital Investment Management LP90,000$94K0.1%-93.0%0.120% 2/17/2025Shay Capital LLC50,000$52K0.0%N/A0.067% 2/17/2025MPM Bioimpact LLC14,705,882$15.44M2.2%N/A19.608% 2/17/2025Millennium Management LLC178,718$188K0.0%+24.2%0.238% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025Citadel Advisors LLC29,900$31K0.0%N/A0.040% 2/17/2025Allostery Investments LP950,166$998K1.0%N/A1.267% 2/17/2025Ally Bridge Group NY LLC1,576,762$1.66M1.4%-10.3%2.102% 2/14/2025Jane Street Group LLC27,395$29K0.0%N/A0.037% 2/14/2025Northern Trust Corp113,565$119K0.0%-34.2%0.151% 2/14/2025Blue Owl Capital Holdings LP6,357,928$6.68M1.6%+17.5%8.477% 2/13/2025Marshall Wace LLP203,286$213K0.0%N/A0.271% 2/13/2025Affinity Asset Advisors LLC1,015,340$1.07M0.1%-23.1%1.354% 2/13/2025Walleye Capital LLC166,306$175K0.0%+51.7%0.222% 2/13/2025Renaissance Technologies LLC338,435$355K0.0%+412.8%0.451% 2/13/2025ADAR1 Capital Management LLC351,094$369K0.1%-6.1%0.468% 2/12/2025Landscape Capital Management L.L.C.90,000$94K0.0%N/A0.120% 2/12/2025Geode Capital Management LLC628,729$661K0.0%+9.2%0.838% 2/12/2025Franklin Resources Inc.4,003,380$4.20M0.0%+115.9%5.338% 1/17/2025Clear Harbor Asset Management LLC57,804$61K0.0%+60.6%0.077% 11/27/2024Franklin Resources Inc.1,853,988$3.69M0.0%N/A2.472% 11/16/2024Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward) CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 26 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were MPM Bioimpact LLC ($15.44M), Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($6.68M), Driehaus Capital Management LLC ($4.53M), Franklin Resources Inc. ($4.20M), Nantahala Capital Management LLC ($3.88M), and Opaleye Management Inc. ($1.53M).Learn more on Context Therapeutics' institutional investors. What percentage of Context Therapeutics' stock is owned by institutional investors? 14.03% of Context Therapeutics' stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics' stock? Of the 22 institutional investors that purchased Context Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: MPM Bioimpact LLC ($14.71M), Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($6.11M), Franklin Resources Inc. ($4.00M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), and Affinity Asset Advisors LLC ($1.35M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 21,510,637 shares in the last 24 months. This purchase volume represents approximately $24.33M in transactions. Which of Context Therapeutics' major shareholders have been selling company stock? Of the 10 institutional investors that sold Context Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Velan Capital Investment Management LP ($1.20M), Affinity Asset Advisors LLC ($803.13K), Ally Bridge Group NY LLC ($728.78K), Great Point Partners LLC ($484.37K), Qube Research & Technologies Ltd ($67.53K), Northern Trust Corp ($58.95K), and Landscape Capital Management L.L.C. ($48.78K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 3,493,058 shares in the last 24 months. This volume of shares sold represents approximately $3.81M in transactions. Related Companies DSGN Major Shareholders KRRO Major Shareholders ALT Major Shareholders RCKT Major Shareholders CGC Major Shareholders RAPT Major Shareholders CTMX Major Shareholders AMRN Major Shareholders ANNX Major Shareholders IMAB Major Shareholders This page (NASDAQ:CNTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTX Stock Alerts